The first meningococcal vaccine licensed in the United States — MPSV4 (Menomune; Sanofi Pasteur), which was approved in 1981 — is based on polysaccharides from serogroups A, C, Y and W-135 (Ref.

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

Sanofi Pasteur, the global vaccines business unit of the French drug maker Sanofi, has joined forces with a US government department to develop a novel COVID-19 coronavirus vaccine.

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand for five-component acellular pertussis (5-acP) antigen. Due for completion in ...

sanofi-pasteur and Novartis. She has served on the Novartis advisory board related to meningococcal vaccines. Responsibility for opinions, conclusions and interpretation of data lies with the author.

Sanofi said it would discontinue its phase 3 clinical trial for an E. Coli vaccine after a review by an independent data monitoring committee. The French pharma company said the scheduled review ...

Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...